InfuSystem (NYSEAMERICAN:INFU - Get Free Report) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating in a report released on Thursday.
InfuSystem Stock Down 1.4 %
NYSEAMERICAN INFU traded down $0.11 on Thursday, hitting $7.96. 59,973 shares of the company's stock were exchanged, compared to its average volume of 45,920. The stock has a market capitalization of $168.59 million, a PE ratio of 265.42 and a beta of 1.24. InfuSystem has a 52 week low of $7.87 and a 52 week high of $11.44. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.08 and a quick ratio of 1.66.
Hedge Funds Weigh In On InfuSystem
A number of institutional investors and hedge funds have recently bought and sold shares of the company. Barclays PLC acquired a new position in shares of InfuSystem during the second quarter worth $35,000. BNP Paribas Arbitrage SNC lifted its holdings in InfuSystem by 3,895.0% during the 2nd quarter. BNP Paribas Arbitrage SNC now owns 4,834 shares of the medical instruments supplier's stock worth $47,000 after buying an additional 4,713 shares during the period. Bank of America Corp DE lifted its holdings in InfuSystem by 31.3% during the 1st quarter. Bank of America Corp DE now owns 6,398 shares of the medical instruments supplier's stock worth $50,000 after buying an additional 1,526 shares during the period. California State Teachers Retirement System bought a new stake in shares of InfuSystem in the 2nd quarter valued at about $58,000. Finally, UBS Group AG increased its stake in shares of InfuSystem by 52.4% in the fourth quarter. UBS Group AG now owns 7,672 shares of the medical instruments supplier's stock valued at $67,000 after buying an additional 2,637 shares during the period. Institutional investors and hedge funds own 71.13% of the company's stock.
About InfuSystem
(
Get Free Report)
InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Integrated Therapy Services (ITS) and Durable Medical Equipment Services (DME Services). It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider InfuSystem, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InfuSystem wasn't on the list.
While InfuSystem currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
